Octagon Therapeutics Inc.
http://www.octagontherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Octagon Therapeutics Inc.
Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Bacteria Are Blind To Politics
Evan Loh, CEO of infectious disease drug developer Paratek Pharmaceuticals, explains why eliminating the DISARM ACT, which focused on finding solutions against antimicrobial resistance, from the new coronavirus aid package is a shortsighted move by US congress.
Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B
Celularity launched with $250m to develop cell therapies with technology licensed from Celgene and others, while mRNA specialist Moderna brought in another $500m mega round and Generation Bio closed a $100m Series B to fund ongoing gene therapy programs.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice